UNSPSC 51392505: Cyclopentamine hydrochloride

This classification denotes an adrenergic agent with the molecular formula C9H19N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F551446KF3, chemically known as n,alpha-dimethylcyclopentaneethylamine hydrochloride but more generally known as cyclopentamine hydrochloride, which bears US NIH Compound Identifier 92798. European Medicines Agency schedules Cyclopentamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01528MIG.

Most nations, for tariff and trade purposes, schedule cyclopentamine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, CYCLOPENTAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cyclopentamine hydrochloride bears US NLM identifiers UMLS ID C0770489 and NCI Concept Code C75030. SMILES: CC(CC1CCCC1)NC.CL.

UNSPSC 51392505 Cyclopentamine hydrochloride, a Commodity code, shows minimal relevant recent state and local procurement activity. The two recent opportunities tagged under this code—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs—center on naloxone procurement and pharmacy benefit management rather than cyclopentamine hydrochloride specifically. State and local governments do not appear to be actively soliciting cyclopentamine hydrochloride as a standalone pharmaceutical product in the recent record. The code may be misaligned with the opportunities indexed to it, or procurement under this specific compound remains outside the visible recent state and local notice stream.

No representative recent solicitations for cyclopentamine hydrochloride are present in the source material. Buyers interested in this Commodity should monitor whether future state and local health department, corrections agency, or emergency services solicitations tag the code more accurately, or consider whether the substance is being procured under broader pharmaceutical or controlled-substance family codes instead.